Agios Pharmaceuticals, Inc. (AGIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$33.10-0.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AGIO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue executing and expanding the U.S. commercial launch of AQVESME for thalassemia with growing prescriptions and revenue.
Stated as a priority in 2 of last 2 quarters. AQVESME prescriptions increased from 242 in 2026-Q1 to 442 in 2026-Q2. Correspondingly, U.S. net revenue from mitapivat products grew from $18.8 million to $40.9 million. Management has consistently emphasized this launch and the trajectory shows delivering commercial momentum.
“Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026”
“Strong initial U.S. commercial launch of AQVESME in thalassemia, with 242 prescriptions written as of March 31, 2026”
Prepare for and execute the potential U.S. commercial launch of mitapivat for sickle cell disease following FDA review and approval.
Stated as a priority in 2 of last 2 quarters. Management announced submission plans for mitapivat sNDA in sickle cell disease in 2026-Q1 and FDA Priority Review granted by 2026-Q2 with a PDUFA date of November 1, 2026. The trajectory matches management's stated progress toward potential U.S. launch.
“FDA granted Priority Review for mitapivat sNDA in sickle cell disease with PDUFA goal date November 1, 2026”
“Company plans to submit mitapivat sNDA for sickle cell disease in second quarter of 2026”
Expand and progress the hematology pipeline including licensing cevidoplenib and advancing AG-236 into Phase 2/3 development.
Newly stated in 2026-Q2. Management announced licensing cevidoplenib and advancing AG-236 into Phase 2/3 development. Financials show increased R&D expenses partly due to a $25 million upfront payment for cevidoplenib licensing. This indicates active pipeline diversification and advancement.
“Licensed cevidoplenib for immune thrombocytopenia and advancing AG-236 into Phase 2/3 development for polycythemia vera”
Target to achieve over $1 billion in peak global sales from mitapivat and related products.
Stated in 3 of last 3 quarters. Management reiterated the $1 billion peak sales potential for mitapivat. Revenue grew from $8.7 million in 2025-Q1 to $44.7 million in 2026-Q2, showing early commercial growth but still far from peak sales. The trajectory is delivering early growth but peak sales remain aspirational.
“Agios expects to execute U.S. commercial launch and advance pipeline toward growth”
“2026 marks an important growth inflection point for Agios as we build a sustainable rare disease company”
“Potential to achieve over $1 billion in peak global sales”
Prepare for the potential U.S. commercial launch of mitapivat.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 1.10x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.